aTyr Pharma, Inc., headquartered in San Diego and founded in 2015, focuses on developing medicines by exploring the novel biological pathways of tRNA synthetases. Their main product, efzofitimod, aims to treat pulmonary sarcoidosis by targeting neuropilin-2 to alleviate chronic inflammation and fibrosis.
Paul Schimmel bought 41,052 shares of ATYR on 22 July at $1.74 per share, worth a total of $72K. They now own 354,075 ATYR shares, or a 13% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
